SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS)

38 filings reported holding SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2025.
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 28,023,938 shares of 51,727,908 outstanding shares and own 54% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (11,420,000 shares), RA CAPITAL MANAGEMENT, L.P. (4,401,500 shares), Commodore Capital LP (4,401,500 shares), Woodline Partners LP (2,850,881 shares), Sessa Capital IM, L.P. (2,198,457 shares), BVF INC/IL (932,697 shares), SPHERA FUNDS MANAGEMENT LTD. (566,395 shares), VANGUARD GROUP INC (365,753 shares), HB Wealth Management, LLC (307,500 shares), and AWM Investment Company, Inc. (200,000 shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.